The events surrounding the removal of encainide and flecainide from the Cardiac Arrhythmia Suppression Trial (CAST) and why CAST is continuing with moricizine.
Bigger
J T
JT
Department of Medicine, Columbia University, New York, New York 10032.
D000813:Anilides / Q000009:adverse effects*; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000517:prevention & control*; D016700:Encainide; D005424:Flecainide / Q000009:adverse effects*; D006801:Humans; D008402:Mass Media; D016293:Moricizine; D009316:National Institutes of Health (U.S.); D010640:Phenothiazines / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D014481:United States; D014486:United States Food and Drug Administration
D000813:Anilides; D000889:Anti-Arrhythmia Agents; D010640:Phenothiazines; D016293:Moricizine; D005424:Flecainide; D016700:Encainide